In its 2021 strategy report, the Global Initiative for Chronic Obstructive Lung Disease
states:“we no longer refer to asthma-COPD overlap (ACO), instead we emphasize that …

Although chronic obstructive pulmonary disease (COPD) and asthma are well-characterized
diseases, they can coexist in a given patient. The term asthma–COPD overlap (ACO) was …

Background Frequent and highly prevalent as comorbidities in Chronic Obstructive
Pulmonary Disease (COPD) patients, both depression and anxiety seem to have an impact …

This article details the GesEPOC 2021 recommendations on the diagnosis and treatment of
COPD exacerbation syndrome (CES). The guidelines propose a definition-based syndromic …

Due to their potent anti-inflammatory capacity (particularly in predominantly eosinophilic
inflammation) and immunosuppressive properties, inhaled corticosteroids (ICSs) are widely …

Purpose Role of triple therapy in chronic obstructive pulmonary disease (COPD)
management is supported by growing evidence, but consensus is lacking on various …

Background COPD is a leading cause of death and disability. COPD therapy goals include
reducing exacerbations and improving symptom control. Single-inhaler triple therapy (SITT) …

COPD is a heterogeneous disorder that shows diverse clinical presentations (phenotypes
and “treatable traits”) and biological mechanisms (endotypes). This heterogeneity implies …

Discharge bundles, comprising evidence-based practices to be implemented prior to
discharge, aim to optimise patient outcomes. They have been recommended to address …

Inhaled bronchodilators (alone or in combination) are the cornerstone of treatment for
symptomatic patients with COPD, either as initial/first-line treatment or for second …